Can Solazyme Meet These Numbers?
Solazyme (NAS: SZYM) is expected to report Q4 earnings on Feb. 20. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Solazyme's revenues will wane -40.3% and EPS will remain in the red.
The average estimate for revenue is $8.9 million. On the bottom line, the average EPS estimate is -$0.31.
Revenue details
Last quarter, Solazyme tallied revenue of $8.6 million. GAAP reported sales were 4.0% lower than the prior-year quarter's $8.9 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS details
Last quarter, non-GAAP EPS came in at -$0.32. GAAP EPS were -$0.37 for Q3 compared to -$0.24 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
Recent performance
For the preceding quarter, gross margin was 84.5%, 930 basis points worse than the prior-year quarter. Operating margin was -269.5%, 11,270 basis points worse than the prior-year quarter. Net margin was -262.2%, 10,460 basis points worse than the prior-year quarter.
Looking ahead
The full year's average estimate for revenue is $44.7 million. The average EPS estimate is -$1.11.
Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 365 members out of 384 rating the stock outperform, and 19 members rating it underperform. Among 85 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 77 give Solazyme a green thumbs-up, and eight give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Solazyme is outperform, with an average price target of $18.50.
Is Solazyme the right energy stock for you? Read about a handful of timely, profit-producing plays on expensive crude in "3 Stocks for $100 Oil." Click here for instant access to this free report.
Add Solazyme to My Watchlist.
The article Can Solazyme Meet These Numbers? originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool owns shares of Solazyme. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
